The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder

International Journal of Neuropsychopharmacology

Volumn 11, Issue 6, 2008, Pages 811-825

  Flaisher Grinberg, Shlomit ^a   Klavir, Oded ^a   Joel, Daphna ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Extinction; Obsessive compulsive disorder (OCD); Post training signal attenuation; Rat

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; 8 [5 [2,4 DIMETHOXY 5 (4 TRIFLUOROMETHYLPHENYLSULFONAMIDO)PHENYL] 5 OXOPENTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; GLEMANSERIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; ALPHA-PHENYL-1-(2-PHENYLETHYL)-4-PIPERIDINEMETHANOL; AMPHETAMINE DERIVATIVE; PIPERIDINE DERIVATIVE; SPIRO COMPOUND; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORBITAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; REINFORCEMENT; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; TASK PERFORMANCE; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; COMPULSION; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; INSTRUMENTAL CONDITIONING; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

AMPHETAMINES; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; COMPULSIVE BEHAVIOR; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; EXTINCTION, PSYCHOLOGICAL; MALE; OBSESSIVE-COMPULSIVE DISORDER; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SPIRO COMPOUNDS; SULFONAMIDES;

EID: 50849118848     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114570800847X     Document Type: Article

References (77)

1. Acuna-Castillo C, Villalobos C, Moya PR, Saez P, Cassels BK, Huidobro-Toro JP (2002). Differences in potency and efficacy of a series of phenylisopropylamine/ phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. British Journal of Pharmacology 136, 510-519.
2. Adinoff B (2004). Neurobiologic processes in drug reward and addiction. Harvard Review of Psychiatry 12, 305-320.
3. Albert U, Bergesio C, Pessina E, Maina G, Bogetto F (2002). Management of treatment resistant obsessive-compulsive disorder. Algorithms for pharmacotherapy. Panminerva Medica 44, 83-91.
4. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Press.
5. Aloyo VJ, Dave KD, Rahman T, Harvey JA (2001). Selective and divergent regulation of cortical 5-HT(2A) receptors in rabbit. Journal of Pharmacology and Experimental Therapeutics 299, 1066-1072.
6. Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083-1152.
7. Baxter G, Kennett G, Blaney F, Blackburn T (1995). 5-HT2 receptor subtypes: a family re-united? Trends in Pharmacological Sciences 16, 105-110.
8. Bickerdike MJ (2003). 5-HT2C receptor agonists as potential drugs for the treatment of obesity. Current Topics in Medicinal Chemistry 3, 885-897.
9. Bonhaus DW, Rocha CL, Dawson MW, Eglen RM (1998). Absorption and brain penetration of a high affinity, highly selective 5-HT2C receptor antagonist, RS-102 221. Annals of the New York Academy of Science 861, 269.
10. Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM (1997). RS-102 221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 36, 621-629.
11. Bös M, Jenck F, Martin JR, Moreau JL, Sleight AJ, Wichmann J, Widmer U (1997). Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. Journal of Medicinal Chemistry 40, 2762-2769.
12. 2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology.
13. Carlsson ML (2001). On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 25, 5-26.
14. Clarke H, Walker S, Dalley J, Robbins T, Roberts A (2007). Cognitive inflexibility after prefrontal serotonin depletion is behaviorally and neurochemically specific. Cerebral Cortex 17, 18-27.
15. Clarke HF, Dalley JW, Crofts HS, Robbins TW, Roberts AC (2004). Cognitive inflexibility after prefrontal serotonin depletion. Science 304, 878-880.
16. Clarke HF, Walker SC, Crofts HS, Dalley JW, Robbins TW, Roberts AC (2005). Prefrontal serotonin depletion affects reversal learning but not attentional set shifting. Journal of Neuroscience 25, 532-538.
17. Conductier G, Crosson C, Hen R, Bockaert J, Compan V (2005). 3,4-N-methlenedioxymethamphetamine-induced hypophagia is maintained in 5-HT1B receptor knockout mice, but suppressed by the 5-HT2C receptor antagonist RS 102221. Neuropsychopharmacology 30, 1056-1063.
18. Dave KD, Harvey JA, Aloyo VJ (2002). A novel behavioral model that discriminates between 5-HT2A and 5-HT2C receptor activation. Pharmacology Biochemistry and Behavior 72, 371-378.
19. Dougherty DD, Rauch SL, Jenike MA (2004). Pharmacotherapy for obsessive-compulsive disorder. Journal of Clinical Psychology 60, 1195-1202.
20. El Mansari M, Blier P (2006). Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 30, 362-373.
21. Engleman EA, Murphy JM, Zhou FC, Hingtgen JN (1992). Response suppression induced with selective 5-HT agonists can be differentially blocked with LY53857 in an animal model of depression. Neurochemical Research 17, 483-488.
22. Friedlander L, Desrocher M (2006). Neuroimaging studies of obsessive-compulsive disorder in adults and children. Clinical Psychology Reviews 26, 32-49.
23. Giorgetti M, Tecott LH (2004). Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. European Journal of Pharmacology 488, 1-9.
24. Glennon RA, Raghupathi R, Bartyzel P, Teitler M, Leonhardt S (1992). Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors : evidence for a lack of selectivity. Journal of Medicinal Chemistry 35, 734-740.
25. Goudreau JL, Manzanares J, Lookingland KJ, Moore KE (1993). 5HT2 receptors mediate the effects of stress on the activity of periventricular hypophysial dopaminergic neurons and the secretion of alpha-melanocyte- stimulating hormone. Journal of Pharmacology and Experimental Therapeutics 265, 303-307.
26. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF (1996). Role of 5-HT in stress, anxiety, and depression. Pharmacology Biochemistry and Behavior 54, 129-141.
27. Graf M (2006). 5-HT2c receptor activation induces grooming behaviour in rats : possible correlations with obsessive-compulsive disorder. Neuropsychopharmacologia Hungarica 8, 23-28.
28. Graf M, Kantor S, Anheuer ZE, Modos EA, Bagdy G (2003). m-CPP-induced self-grooming is mediated by 5-HT2C receptors. Behavioural Brain Research 142, 175-179.
29. Greenberg BD, Benjamin J, Martin JD, Keuler D, Huang SJ, Altemus M, Murphy DL (1998). Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Psychopharmacology (Berlin) 140, 434-444.
30. Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J (2004). Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 50, 200-205.
31. Grottick AJ, Fletcher PJ, Higgins GA (2000). Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior. Journal of Pharmacology and Experimental Therapeutics 295, 1183-1191.
32. Hawkins MF, Uzelac SM, Baumeister AA, Hearn JK, Broussard JI, Guillot TS (2002). Behavioral responses to stress following central and peripheral injection of the 5-HT(2) agonist DOI. Pharmacology Biochemistry and Behavior 73, 537-544.
33. Herin DV, Liu S, Ullrich T, Rice KC, Cunningham KA (2005). Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology (Berlin) 178, 505-513.
34. Higgins GA, Enderlin M, Haman M, Fletcher PJ (2003). The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berlin) 170, 309-319.
35. Higgins GA, Fletcher PJ (2003). Serotonin and drug reward: focus on 5-HT2C receptors. European Journal of Pharmacology 480, 151-162.
36. Higgins GA, Ouagazzal AM, Grottick AJ (2001). Influence of the 5-HT(2C) receptor antagonist SB242,084 on behaviour produced by the 5-HT(2) agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine. British Journal of Pharmacology 133, 459-466.
37. Jentsch JD, Taylor JR (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berlin) 146, 373-390.
38. Joel D (2006). The signal attenuation rat model of obsessive-compulsive disorder : a review. Psychopharmacology (Berlin) 186, 487-503.
39. Joel D, Avisar A (2001). Excessive lever pressing following post-training signal attenuation in rats : a possible animal model of obsessive compulsive disorder? Behavioural Brain Research 123, 77-87.
40. Joel D, Ben-Amir E, Doljansky J, Flaisher S (2004). 'Compulsive' lever-pressing in rats is attenuated by the serotonin re-uptake inhibitors paroxetine and fluvoxamine but not by the tricyclic antidepressant desipramine or the anxiolytic diazepam. Behavioral Pharmacology 15, 241-252.
41. Joel D, Doljansky J, Roz N, Rehavi M (2005a). Role of the orbital cortex and of the serotonergic system in a rat model of obsessive compulsive disorder. Neuroscience 130, 25-36.
42. Joel D, Doljansky J, Schiller D (2005b). 'Compulsive' lever pressing in rats is enhanced following lesions to the orbital cortex, but not to the basolateral nucleus of the amygdala or to the dorsal medial prefrontal cortex. European Journal of Neuroscience 21, 2252-2262.
43. Joel D, Klavir O (2006). The effects of temporary inactivation of the orbital cortex in the signal attenuation rat model of obsessive compulsive disorder. Behavioral Neuroscience 120, 976-983.
44. Kalivas PW, Volkow ND (2005). The neural basis of addiction : a pathology of motivation and choice. American Journal of Psychiatry 162, 1403-1413.
45. Kehne JH, McCloskey TC, Baron BM, Chi EM, Harrison BL, Whitten JP, Palfreyman MG (1991). NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. European Journal of Pharmacology 193, 283-292.
46. Kennett GA, Lightowler S, de Biasi V, Stevens NC, Wood MD, Tulloch IF, Blackburn TP (1994). Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 33, 1581-1588.
47. Khanna S, John JP, Reddy LP (2001). Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder. Psychoneuroendocrinology 26, 209-223.
48. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M (2004). Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedeberg's Archives of Pharmacology 370, 114-123.
49. Koskinen T, Ruotsalainen S, Puumala T, Lappalainen R, Koivisto E, Mannisto PT, Sirvio J (2000). Activation of 5-HT2A receptors impairs response control of rats in a five-choice serial reaction time task. Neuropharmacology 39, 471-481.
50. Liao RM, Chang YH (2001). Different effects of 5-HT receptor agonists on operant response in rats under DRL 10-s and DRL 30-s schedules. Proceedings of the National Science Council, Republic of China B 25, 223-232.
51. Martin JR, Ballard TM, Higgins GA (2002). Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacology Biochemistry and Behaviour 71, 615-625.
52. Mackintosh NJ (1974). The Psychology of Animal Learning. London: Academic Press.
53. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR (2002). The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. British Journal of Pharmacology 135, 170-180.
54. Miguel EC, Shavitt RG, Ferrao YA, Brotto SA, Diniz JB (2003). How to treat OCD in patients with Tourette syndrome. Journal of Psychosomatic Research 55, 49-57.
55. Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry 67, 1735-1740.
56. Muller CP, Huston JP (2006). Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine. Trends in Pharmacological Sciences 27, 105-112.
57. Nic Dhonnchadha BA, Hascoet M, Jolliet P, Bourin M (2003a). Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice. Behavioural Brain Research 147, 175-184.
58. Nic Dhonnchadha BA, Bourin M, Hascoet M (2003b). Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behavioural Brain Research 140, 203-214.
59. Ouagazzal A, Grottick AJ, Moreau J, Higgins GA (2001). Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology 25, 565-575.
60. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates (4th edn). San Diego: Academic Press.
61. Pehek EA, Nocjar C, Roth BL, Byrd TA, Mabrouk OS (2006). Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31, 265-277.
62. Popova NK, Amstislavskaya TG (2002). 5-HT2A and 5-HT2C serotonin receptors differentially modulate mouse sexual arousal and the hypothalamo-pituitary-testicular response to the presence of a female. Neuroendocrinology 76, 28-34.
63. Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ (1999). Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. British Journal of Pharmacology 128, 13-20.
64. Ramos M, Goni-Allo B, Aguirre N (2005). Administration of SCH 23390 into the medial prefrontal cortex blocks the expression of MDMA-induced behavioral sensitization in rats : an effect mediated by 5-HT2C receptor stimulation and not by D1 receptor blockade. Neuropsychopharmacology 30, 2180-2191.
65. Ripoll N, Hascoet M, Bourin M (2006). Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test-retest paradigm in mice. Behavioural Brain Research 166, 131-139.
66. Rojas-Corrales MO, Gibert-Rahola J, Mico JA (2007). Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior. Psychopharmacology (Berlin) 190, 221-231.
67. Sasson Y, Zohar J (1996). New developments in obsessive-compulsive disorder research: implications for clinical management. International Clinical Psychopharmacology 11 (Suppl. 5), 3-12.
68. Schmidt CJ, Taylor VL, Abbate GM, Nieduzak TR (1991). 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4- methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis : reversal by L-dopa. Journal of Pharmacology and Experimental Therapeutics 256, 230-235.
69. Sramek JJ, Robinson RE, Suri A, Cutler NR (1995). Efficacy trial of the 5-HT2 antagonist MDL11,939 in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 15, 20-22.
70. Stahl SM (2000). Essential Psychopharmacology. Neuroscientific Basis and Practical Application (2nd edn). Cambridge: Cambridge University Press.
71. Stein DJ (2002). Obsessive-compulsive disorder. Lancet 360, 397-405.
72. Takahashi H, Takada Y, Urano T, Takada A (2001). Dissociation of systemic and hippocampal modulation of rat locomotor activity by 5-HT(2C) receptors. Neuroscience Research 40, 97-103.
73. Tsaltas E, Kontis D, Chrysikakou S, Giannou H, Biba A, Pallidi S, Christodoulou A, Maillis A, Rabavilas A (2005). Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology. Biological Psychiatry 57, 1176-1185.
74. Van Oekelen D, Luyten WH, Leysen JE (2003). 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sciences 72, 2429-2449.
75. Walker SC, Mikheenko YP, Argyle LD, Robbins TW, Roberts AC (2006). Selective prefrontal serotonin depletion impairs acquisition of a detour-reaching task. European Journal of Neuroscience 23, 3119-3123.
76. Yamauchi M, Tatebayashi T, Nagase K, Kojima M, Imanishi T (2004). Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats. Pharmacology Biochemistry and Behavior 78, 683-689.
77. Zohar J, Zohar-Kadouch RC, Kindler S (1992). Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 43, 210-218.